UCB Exercises Its Option To License A Program From Oncodesign SA Targeting Neurological Diseases

DIJON, France--(BUSINESS WIRE)--ONCODESIGN (Paris:ALONC) (Alternext - ALONC) announced today that it has successfully reached a major milestone in its joint discovery collaboration with UCB that applies to Oncodesign’s Nanocyclix® technology on a kinase target selected by UCB. This collaboration was initiated in October 2013 and aims to leverage the respective expertise of Oncodesign and UCB to bring innovative therapeutic solutions to patients suffering from neurological disorders.

Help employers find you! Check out all the jobs and post your resume.